3.1. Clinical report
The patient is a 22-year-old female from a small village in Ilam, Iran. When she was 10 years old, the earliest clinical manifestations became apparent and she was referred to a physician due to the existence of tendon xanthomas on her hands, elbows and knees. She was aware of her severe hypercholesterolemia since she was 11 years old, with an LDL-C concentration of 720 mg/dL. A daily pharmacological treatment of 4 g cholestyramine was initiated. The patient reported that she had undergone subaortic web resection and aortoplasty due to her uncontrolled hyperlipidemia in 2011 at the age of 13. She came to our cardiovascular center in Tehran in January 2015 for the study of her hypercholesterolemia. Bilateral corneal arcus, xanthomas and xanthelasmas were present. The plasma lipid profile was performed revealing severe hypercholesterolemia. Secondary causes of hypercholesterolemia, including renal diseases, diabetes mellitus and thyroid disease were ruled out. Liver enzymes levels were normal. Her physical examination revealed blood pressure of 110/70 mmHg and body mass index (BMI) of 29 kg/m2. At the age of 17 years, assessment of coronary arteries by coronary angiography revealed 50% ostial lesion of the left main artery and the right coronary artery was retrogradely filled by the left system. There was also a significant pressure gradient of 80 mmHg in favor of significant AVS. On echocardiography, she had normal left ventricular systolic function and there was serial stenosis. The mitral and the tricuspid valves had mild regurgitation and the pulmonary artery pressure was normal. Therefore, although the patient was candidate for CABG and AVR, she rejected this surgery for personal reasons. Genetic analysis determined a homozygous LDLRAP1 gene variant NM_015627.2: c.649G>T, NP_056442.2: p. Glu217Ter, which caused ARH disease. The other genes involved in FH including LDLR, PCSK9 and APOB didn't have any known pathologic mutation. A pharmacological treatment with rosuvastatin (60 mg/day) plus ezetimibe (10 mg/day) was initiated. In May 2018, an angiography was performed and she was diagnosed with severe SVAS resulted in significant stenotic lesions of the coronary arteries and aortic valve. It was suggested that the patient should have CABG and AVR, but she refused to do so again. The family history displayed that the parents were cousins and had given birth four children (two males and two females), two of whom had passed away for unknown reasons. The lipid profile of the patient’s mother (at the age of 44 years) was at normal range: TC—198 mg/dL, LDL-C—105 mg/dL, HDL-C—62 mg/dL and TG—150 mg/dL. The patient’s father had died at the age of 42 years from coronary artery disease and his lipid profile is unavailable (Fig. 1).
3.2. Laboratory Testing
In January 2015, when the patient (at the age of 17 years) came to our cardiovascular center, the plasma lipid profile was performed, which showed severe hypercholesterolemia: total cholesterol (TC) 520 mg/dL, low-density lipoproteins-cholesterol (LDL-C) 446 mg/dL, high-density lipoproteins-cholesterol (HDL-C) 57 mg/dL and triglycerides (TG) 93 mg/dL. We started a pharmacological treatment with rosuvastatin (60 mg/day) plus ezetimibe (10 mg/day). The treatment process from January 2015 and the consequent lipid responses are shown in Table 1. Undergoing this treatment, the cutaneous xanthomas decreased markedly and also a remarkable reduction of plasma LDL-C was determined (from 402.5 ±31.1 to 103.8 ± 26.02 mg/dL) associated with a significant increase in alanine aminotransferase (ALT, from 16.25 ± 6.05 to 49.2 ±25.2 UI/L). The treatment produced no significant side effects. Table 1 shows the changes in lipid levels obtained in baseline situation (mean of 4 determinations) and along cholesterol-lowering treatment (mean of monthly determinations).
Table 1. Evolution of lipid profile of the patient before and during treatment with rosuvastatin (60 mg/day) plus ezetimibe (10 mg/day)
Plasma parameter
|
Before drugs
|
R60 + E10
|
Percent change
|
P*
|
TC mg/dL
|
482.25 ± 28.4
|
169.7 ±32.1
|
-64.8
|
< .0001
|
LDL-C mg/dL
|
402.5 ± 31.1
|
103.8 ± 26.02
|
-74.2
|
< .001
|
HDL-C mg/dL
|
61.5 ± 5.4
|
48.1 ± 6.8
|
-21.8
|
< .01
|
TG mg/dL
|
81.5 ± 13.6
|
62.8 ± 11.5
|
-22.9
|
< .052
|
TC, total cholesterol; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; TG, triglycerides.
Values are mean ± SD. *Comparisons were performed by student’s test for paired data.
3.3. Genetic Analysis
The results of NGS analysis did not identify any pathogenic changes in LDLR, PCSK9 and APOB. However, a novel homozygous variant, c.649G>T, in the LDLRAP1 gene, was detected in the patient. The identified mutation c.649G>T leads to the formation of stop codon at amino acid residue 217 of ARH protein (p. Glu217Ter). Sanger sequencing was used to validate the presence of the new variant identified by NGS (Fig. 2). The same mutation c.649G>T was identified in the LDLRAP1 in heterozygosity for her mother and living brother. According to the American College of Medical Genetics and Genomics (ACMG) guideline 2015 (17), this nonsense variant can be assumed to disrupt the function of protein using nonsense-mediated decay of an altered transcript. However, in silico analysis were performed by available software tools, including CADD (Combined Annotation Dependent Depletion), SIFT and MutationTaster to predict pathogenicity of the variant. The results of the analysis predicted this variant as damaging due to a stop codon mutation in exon 7 of the LDLRAP1 (Table 2). Furthermore, the sequences were mapped to the GRCh37/hg19 human reference sequence. Data bases used for assessment were Online Mendelian Inheritance in Man (www.omim.org); Human Gene Mutation Database (HGMD® Public) (www.biobaseinternational.com/hgmd) from BIOBASE Corporation and Gene Tests (www.genetests.org).
These software tools predicted the pathogenic effect of the variant. The identified nonsense variant was absent in HGMD, dbSNP version 147, ClinVar databases, Iranome and Exome Sequencing Project (ESP). This variant was not found in the literature as well. The novel variant was named c.649G>T, based on Human Genome Variation Society (HGVS) nomenclature standards and determined based on NM_015627.2 and NP_056442.2. The sequence variant was submitted to ClinVar database.
Table 2. Several online databases that used to predict the pathogenicity of c.649G>T, p.Glu217Ter in the family.
Gene
|
NM
|
NP
|
Exon
|
Alteration
|
In silico analysis tools
|
dbSNP ID
|
LDLRAP1
|
NM_015627
|
NP_056442
|
7
|
Nucleic Acid
|
Amino Acid
|
MutationTaster
|
CADD
|
SIFT
|
novel
|
c.649G>T
|
p.Glu217Ter
|
Disease causing
|
42
|
Damaging
|